OR WAIT null SECS
C-tasc Receives “Outstanding” Ratings from NIH for
the Coordination, Collection, and Analysis of Clinical Data
Clinical Trials Solution Company Recognized for Statistical Work
on Women and Infants Transmission Study (WITS)
Baltimore, Md.-(March 2, 2009)-Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, announced today that it has received a glowing Contractor Performance Report from the National Institutes of Health (NIH) for its statistical and clinical coordinating center work on the Women and Infants Transmission Study (WITS). In the report, C-TASC received three scores of “outstanding”-the highest mark NIH reserves for those contractors that significantly exceed performance expectations – for its quality of service, timeliness of performance and business relations, as well as an “excellent” score for cost control.
According to the comments included in the evaluation, C-TASC’s team was “pleasant and cooperative” to work with, always delivered tasks on time or ahead of time and achieved cost savings for the government in the process. Its “performance throughout the contract was above expectations and could serve as a model for other similar contracts.”
Led by President Dr. Bruce Thompson as principal investigator, C-TASC coordinated all of the clinical aspects of the multi-center study contracted by the National Institute of Allergy and Infectious Diseases (NIAID). Over a ten-year period from April of 1998 to June of 2008, C-TASC managed data collection at six clinical sites from more than 3,000 women and 2,700 infants born to them. The main objectives of the study were to identify and characterize factors that influence maternal-infant transmission of HIV; develop and evaluate methods for early diagnosis of HIV in perinatally exposed infants; and identify and characterize factors that influence HIV disease progression in HIV-infected pregnant and postpartum women and children.
“Our team prides itself in conducting clinical studies using methods that are most efficient in terms of safety, accuracy, time and cost,” said Dr. Bruce Thompson, president, C-TASC. “To receive such a positive evaluation from NIH for our work on a study that is as important to public health as WITS is a great testament to the effort we put into producing valuable results in a timely and cost-effective manner.”
Based in Baltimore, Maryland, Clinical Trials & Surveys Corp. (C-TASC) is a clinical trials solutions company that supports best practices management of clinical trials, clinical cohort studies, case/control studies, clinical registries and laboratory studies. Founded in 1989, C-TASC provides clients with complete research management including medical and statistical study design, project management, performance monitoring and data quality control and analysis as well as support for study publication and presentations. C-TASC’s professional services group has a successful research history in cancer, cardiovascular disease, AIDS, pulmonary disease, Cystic Fibrosis, pharmaco-epidemiology and bio-repository establishment and coordination. For more information about C-TASC’s projects, products and services, please visit www.c-tasc.com